Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.83 |
| ▸ | AKT2 | P31751 | 18/20 | 0.83 |
| ▸ | AKT3 | Q9Y243 | 15/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31455810 | 0.99 | AKT1 (0.84) | AKT1AKT2AKT3CYP2C9CYP3A4 | |
| SCHEMBL27226402 | 0.92 | AKT1 (0.74) | AKT1AKT2AKT3CYP2C9CYP3A4 | |
| SCHEMBL30815051 | 0.92 | AKT1 (0.74) | AKT1AKT2AKT3CYP2C9CYP3A4 | |
| SCHEMBL27227112 | 0.91 | AKT1 (0.70) | AKT1AKT2AKT3CYP2C9CYP3A4 | |
| SCHEMBL30815155 | 0.91 | AKT1 (0.70) | AKT1AKT2AKT3CYP2C9CYP3A4 | |
| SCHEMBL27309931 | 0.91 | AKT1 (0.70) | AKT1AKT2AKT3CYP2C9CYP3A4 | |
| SCHEMBL2176395 | 0.91 | AKT1 (1.00) | AKT1AKT2AKT3CYP2C9CYP3A4 | |
| SCHEMBL25385228 | 0.90 | AKT1 (0.86) | AKT1AKT2AKT3CYP2C9CYP3A4 | |
| SCHEMBL30574960 | 0.90 | AKT1 (0.86) | AKT1AKT2AKT3CYP2C9CYP3A4 | |
| SCHEMBL29324409 | 0.87 | AKT1 (0.82) | AKT1AKT2AKT3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | AKT1 1/4885AKT2 3/4885AKT3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.